PSP Platform vs PSP Operator: Roles, Risks and Contracts in KSA

PSP Platform vs PSP Operator: Roles, Risks and Contracts in KSA

One of the most consequential—and least understood—distinctions in Saudi Arabia's patient support program market is the difference between a PSP platform and a PSP operator. Pharmaceutical brand teams that conflate the two end up with contracts that leave critical responsibilities unassigned, liability gaps that only become visible during an adverse event, and program governance that no one actually owns.

This article explains the three models for delivering PSP services in KSA, defines the responsibilities that belong to each party, provides a contract clause checklist, and helps brand teams identify which model fits their program design and commercial context.

---

Key Takeaways

• Saudi Arabia's PSP market operates across three distinct delivery models: fully outsourced, platform-plus-operator, and in-house. Each creates a different liability and governance structure.
• The most common contract gap in KSA PSP programs is adverse event (AE) ownership and reporting pathway — when both the sponsor and operator believe the other party is handling reconciliation, neither is.
• In a platform-plus-operator model, the platform vendor's role ends at the technology boundary; the operator's role begins there. This line must be drawn explicitly in both contracts.
• Keywords are unvalidated editorial hypotheses (H); no search volume claims are made.

---

Three Models for PSP Delivery in Saudi Arabia

Model 1: Fully Outsourced (Operator-Led)

In the fully outsourced model, the sponsor contracts with a single PSP operator who manages the entire program: patient intake, nurse educators, coordinators, pharmacist support, clinical follow-up, and reporting — typically using the operator's own proprietary technology or a vendor platform embedded within their service.

Who it suits: Sponsors launching their first Saudi PSP, or those managing lower-volume programs where the overhead of managing technology and operations separately isn't warranted. Also common for rare-disease programs where the operator provides highly specialized clinical support that the sponsor cannot build in-house.

Risk profile: The sponsor has limited visibility into day-to-day program operations and relies on the operator's reporting. Technology flexibility is constrained — if the operator uses a proprietary system, switching operators likely means rebuilding patient data and workflows. AE ownership must be explicitly contracted; in a fully outsourced model, the operator typically manages first-tier AE capture and escalation, but the sponsor remains the SFDA-registered responsible party.

Model 2: Platform Plus Operator (Hybrid)

In the platform-plus-operator model, the sponsor contracts separately with a technology vendor (the platform) and an operational service provider (the operator). The platform provides the digital infrastructure — patient app, coordinator portal, reporting dashboard, AE capture workflows — while the operator provides the human clinical and coordination resources who use that platform to deliver services.

Who it suits: Sponsors with existing operator relationships who want to upgrade the technology layer without changing their clinical team. Also common for large-volume programs where the sponsor wants to maintain data ownership and portability independent of the operator.

Risk profile: The governance boundary between platform and operator responsibilities must be precisely defined. When a patient reports a symptom through the app, is the platform's AE capture workflow sufficient to trigger the operator's clinical follow-up protocol? This handoff is where most hybrid-model program failures originate.

Model 3: In-House (Sponsor-Operated)

In the in-house model, the sponsor contracts directly with the technology platform and operates the program with their own medical science liaisons, nurse educators, and support staff. This model is rare in Saudi Arabia for most specialty brands but occurs in large pharmaceutical companies with established patient services teams.

Who it suits: Sponsors with existing patient services infrastructure who want maximum program control and direct patient data ownership. Requires significant internal resourcing commitment.

Risk profile: All operational responsibilities rest with the sponsor. This includes AE reconciliation, coordinator training, patient complaint management, and regulatory reporting. Technology vendor scope is narrowly defined; all human-layer failure modes are sponsor-owned.

---

RACI Matrix: Responsibilities Across the Three Models

A well-structured RACI clarifies which party is Responsible, Accountable, Consulted, and Informed for each program function. The following matrix covers the most commonly disputed responsibilities.

Note: This matrix represents general role assignments; specific responsibilities must be explicitly defined in contracts. RACI models built with an operator partner are strongly preferred over sponsor-drafted assumptions. [VERIFY WITH BRAND — specific role assignments should reflect contracted terms and legal review.]

---

Contract Clauses That Commonly Create Gaps

Regardless of delivery model, the following contract areas are most frequently underspecified in Saudi PSP agreements — and most consequential when a problem occurs.

Safety Data Exchange Agreement (SDEA)

Every PSP contract involving a technology vendor or operator should include a Safety Data Exchange Agreement that defines: how potential AEs are identified, documented, and communicated to the sponsor; the timescales for escalation; the format of AE data transfer; and who bears responsibility for timely submission to SFDA if required.

The absence of a formal SDEA — or one copied from a previous program without review — is the single most common source of pharmacovigilance compliance risk in outsourced PSP operations.

Data Controller and Processor Designation

Under Saudi PDPL, health data is sensitive personal data. Every contract in the PSP chain must explicitly designate the data controller (the party determining the purpose and means of processing — almost always the sponsor) and all data processors (the platform vendor, the operator, any sub-contractors). Gaps in this chain create liability.

A data processing agreement (DPA) must accompany every contract involving health data processing. The DPA should address: data retention periods, deletion and return obligations, sub-processor approval rights, breach notification timescales, and data subject rights fulfillment.

Service Level Agreements and Clinical Escalation Timelines

For programs involving clinical follow-up — particularly those supporting patients on complex biologics or rare-disease therapies — SLA clauses must define escalation timelines for clinical concerns, not just platform uptime. A 99.9% uptime SLA means nothing if the contractual response time for a reported AE is 48 business hours.

Operator Switching and Data Portability

If the sponsor contracts separately with a platform and an operator, the platform contract should include explicit data portability provisions: the sponsor's right to export all patient data in a structured, interoperable format in the event of operator termination. Without this clause, changing operators may be practically impossible without restarting the program from scratch.

Cost Implications of Model Choice

Fully outsourced models typically have lower apparent startup costs but higher per-patient or per-interaction costs, with limited transparency into the operator's technology overhead. Platform-plus-operator models require parallel contract management and careful governance design but provide more cost transparency over time. In-house models have the highest setup investment but lowest per-patient marginal cost at scale.

Request itemised pricing for each model at your expected Year 1 enrollment and Year 2 active patient counts before comparing models on cost alone.

---

When Each Model Fits

---

FAQ

Do we need both a platform vendor and an operator? Not necessarily. In the fully outsourced model, the operator provides both the platform and the services. The question is whether bundling them creates acceptable risk and flexibility for your program's specific requirements. The answer depends on the volume, complexity, and your data ownership needs.

Who owns patient data in a PSP — sponsor, operator, or platform vendor? Under Saudi PDPL, the data controller (almost always the sponsor) determines the purpose of processing. The operator and platform vendor are data processors. Patient data belongs to the data subject — it must be handled according to their consent, and the sponsor as controller is ultimately accountable for how it is processed. This must be reflected explicitly in all contracts. [VERIFY WITH BRAND — specific data ownership obligations require legal review.]

Who reports adverse events to SFDA? The sponsor, as the SFDA-registered marketing authorization holder, is ultimately responsible for adverse event reporting. The operator or platform may manage first-tier capture and escalation, but the reporting obligation cannot be contractually delegated to a service provider without maintaining the sponsor's accountability. Any SDEA must reflect this.

Can we switch operators if the program isn't performing? Only if the platform contract includes data portability provisions. If the platform is proprietary to the operator, switching may require rebuilding the program. This is the most important reason to contract the platform and operator separately — it preserves the sponsor's ability to change operational delivery without losing the program infrastructure.

What is the typical cost difference between models? Cost varies significantly by program volume, therapy complexity, and service scope. Platform-plus-operator models typically show lower total cost of ownership at higher patient volumes; outsourced models often have lower apparent entry costs. Request itemised proposals across all three models at your expected volume before making a model decision on cost grounds. [VERIFY WITH BRAND — specific pricing references require commercial validation.]

---

Published: 2026-11-05 · Author: CareSync Team · This article provides general information about PSP delivery model structures in Saudi Arabia. It does not constitute legal, regulatory, or medical advice. All contract and compliance decisions should be reviewed with qualified legal and regulatory advisors.

---

Ready to map your program model to the right governance structure? Book a CareSync governance workshop →